Immunotherapy for Treatment of Pleural Mesothelioma: Current and Emerging Therapeutic Strategies

被引：0
作者：
Chiec, Lauren [1 ,2 ]
Bruno, Debora S. [1 ,2 ]
机构：
[1] Univ Hosp Seidman Canc Ctr, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2024年 / 25卷 / 19期
关键词：
mesothelioma; immunotherapy; immune checkpoint inhibitor; RELAPSED MALIGNANT MESOTHELIOMA; PEGYLATED ARGININE DEIMINASE; NIVOLUMAB PLUS IPILIMUMAB; OPEN-LABEL; PHASE-II; SINGLE-ARM; INTERNATIONAL-ASSOCIATION; DOUBLE-BLIND; CHEMOTHERAPY; TRIAL;
D O I：
10.3390/ijms251910861
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Pleural mesothelioma is a rare malignancy associated with asbestos exposure and very poor prognosis, with a 5-year overall survival of 12%. Outcomes may vary according to stage at time of diagnosis and histologic subtype. Most recently, clinical trials utilizing dual checkpoint inhibitor regimens and chemotherapy in combination with immune oncologic agents have demonstrated impactful changes in outcomes. In this article, we review studies that have led to the successful implementation of immunotherapy in clinical practice for the treatment of this disease and highlight ongoing clinical trials exploring the use of different immunotherapy strategies for the treatment of pleural mesothelioma. We also discuss the challenges of immunotherapy-based approaches in the context of mesothelioma and future strategies currently being investigated to overcome them.
引用
收藏
页数：18
相关论文
共 107 条
  • [1] A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab
    Adusumilli, Prasad S.
    Zauderer, Marjorie G.
    Riviere, Isabelle
    Solomon, Stephen B.
    Rusch, Valerie W.
    O'Cearbhaill, Roisin E.
    Zhu, Amy
    Cheema, Waseem
    Chintala, Navin K.
    Halton, Elizabeth
    Pineda, John
    Perez-Johnston, Rocio
    Tan, Kay See
    Daly, Bobby
    Araujo Filho, Jose A.
    Ngai, Daniel
    McGee, Erin
    Vincent, Alain
    Diamonte, Claudia
    Sauter, Jennifer L.
    Modi, Shanu
    Sikder, Devanjan
    Senechal, Brigitte
    Wang, Xiuyan
    Travis, William D.
    Gonen, Mithat
    Rudin, Charles M.
    Brentjens, Renier J.
    Jones, David R.
    Sadelain, Michel
    [J]. CANCER DISCOVERY, 2021, 11 (11) : 2748 - 2763
  • [2] Aerts Joachim G, 2024, Lancet Oncol, V25, P865, DOI 10.1016/S1470-2045(24)00191-8
  • [3] Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human
    Aerts, Joachim G. J. V.
    de Goeje, Pauline L.
    Cornelissen, Robin
    Kaijen-Lambers, Margaretha E. H.
    Bezemer, Koen
    van der Leest, Cor H.
    Mahaweni, Niken M.
    Kunert, Andre
    Eskens, Ferry A. L. M.
    Waasdorp, Cynthia
    Braakman, Eric
    van der Holt, Bronno
    Vulto, Arnold G.
    Hendriks, Rudi W.
    Hegmans, Joost P. J. J.
    Hoogsteden, Henk C.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (04) : 766 - 776
  • [4] Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
    Alley, Evan W.
    Lopez, Juanita
    Santoro, Armando
    Morosky, Anne
    Saraf, Sanatan
    Piperdi, Bilal
    van Brummelen, Emilie
    [J]. LANCET ONCOLOGY, 2017, 18 (05) : 623 - 630
  • [5] First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
    Baas, Paul
    Scherpereel, Arnaud
    Nowak, Anna K.
    Fujimoto, Nobukazu
    Peters, Solange
    Tsao, Anne S.
    Mansfield, Aaron S.
    Popat, Sanjay
    Jahan, Thierry
    Antonia, Scott
    Oulkhouir, Youssef
    Bautista, Yolanda
    Cornelissen, Robin
    Greillier, Laurent
    Grossi, Francesco
    Kowalski, Dariusz
    Rodriguez-Cid, Jeronimo
    Aanur, Praveen
    Oukessou, Abderrahim
    Baudelet, Christine
    Zalcman, Gerard
    [J]. LANCET, 2021, 397 (10272) : 375 - 386
  • [6] Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting
    Baldin, Alexey V.
    Savvateeva, Lyudmila V.
    Bazhin, Alexandr V.
    Zamyatnin, Andrey A., Jr.
    [J]. CANCERS, 2020, 12 (03)
  • [7] Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
    Beatty, Gregory L.
    Haas, Andrew R.
    Maus, Marcela V.
    Torigian, Drew A.
    Soulen, Michael C.
    Plesa, Gabriela
    Chew, Anne
    Zhao, Yangbing
    Levine, Bruce L.
    Albelda, Steven M.
    Kalos, Michael
    June, Carl H.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2014, 2 (02) : 112 - 120
  • [8] Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers
    Beddowes, Emma
    Spicer, James
    Chan, Pui Ying
    Khadeir, Ramsay
    Corbacho, Javier Garcia
    Repana, Dimitra
    Steele, Jeremy P.
    Schmid, Peter
    Szyszko, Teresa
    Cook, Gary
    Diaz, Monica
    Feng, Xiaoxing
    Johnston, Amanda
    Thomson, Jim
    Sheaff, Michael
    Wu, Bor-Wen
    Bomalaski, John
    Pacey, Simon
    Szlosarek, Peter W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (16) : 1778 - +
  • [9] Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma
    Bensaid, Douae
    Blondy, Thibaut
    Deshayes, Sophie
    Dehame, Virginie
    Bertrand, Philippe
    Gregoire, Marc
    Errami, Mohammed
    Blanquart, Christophe
    [J]. CLINICAL EPIGENETICS, 2018, 10 : 79
  • [10] A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) - a randomised feasibility study using the trial within a cohort (TwiC) methodology
    Bibby, Anna C.
    Zahan-Evans, Natalie
    Keenan, Emma
    Comins, Charles
    Harvey, John E.
    Day, Helen
    Rahman, Najib M.
    Fallon, Janet E.
    Gooberman-Hill, Rachael
    Maskell, Nick A.
    [J]. PILOT AND FEASIBILITY STUDIES, 2022, 8 (01)
12345678910